title: Hepatic uptake of technetium-99m HM-PAO in a fetus.
abstract: The normal biodistribution of technetium-99m HM-PAO ([99mTc]HM-PAO) includes significant uptake in the brain, liver, and kidneys. A pregnant patient studied with [99mTc] HM-PAO to confirm brain death provided an opportunity to examine the transplacental distribution of this radio-pharmaceutical in the unborn fetus. Uptake in the fetus after transplacental delivery is almost exclusively hepatic with a small amount of biliary excretion.
authors.affiliation: Department of Nuclear Medicine, Victoria Hospital, London, Ontario, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Maguire
authors.forename: S
authors.initials: S
authors.lastname: Florence
authors.forename: J E
authors.initials: JE
authors.lastname: Powe
authors.forename: P L
authors.initials: PL
authors.lastname: Zabel
authors.forename: A A
authors.initials: AA
authors.lastname: Driedger
mesh_terms: D000328:Adult; D001926:Brain Death / Q000000981:diagnostic imaging*; D005260:Female; D005333:Fetus / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000378:metabolism*; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D010091:Oximes / Q000493:pharmacokinetics; D011247:Pregnancy; D011248:Pregnancy Complications / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019690:Technetium Tc 99m Exametazime
chemical_list: D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime